Trials / No Longer Available
No Longer AvailableNCT04948398
Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis
Post-Trial Access for Guselkumab in Patients With Familial Adenomatous Polyposis Who Are Experiencing Clinical Benefit After Completing 48 Weeks of Treatment in CNTO1959COR1001
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- —
- Age
- —
- Healthy volunteers
- —
Summary
The purpose of this post-trial access (PTA) program is to provide guselkumab to participants with Familial Adenomatous Polyposis (FAP) who are experiencing clinical benefit after completing 48 weeks of treatment in Study CNTO1959COR1001.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Guselkumab | Guselkumab 100 milligrams (mg) will be administered subcutaneously once every 8 weeks. |
Timeline
- First posted
- 2021-07-02
- Last updated
- 2025-02-03
Source: ClinicalTrials.gov record NCT04948398. Inclusion in this directory is not an endorsement.